Acute respiratory
viral infections (ARVI) and
influenza take a leading place in the structure of the general morbidity of the population in most countries of the world. Of etiotropic treatment of
influenza and other ARVI include a wide spectrum of
antiviral drugs, among which are the drugs with a restricted spectrum, basically used in
influenza, and a general spectrum used in
influenza and other ARVI as a prophylactic or therapeutic intention. At present time, there is a widespread
antiviral drug umifenovir. On the mechanism of
antiviral action it refers to the fusion inhibitors of the virus with the cell membrane.
Antiviral activity in vitro
umifenovir studied in several independent laboratories.
Umifenovir active against respiratory viruses such as rhinovirus, adenovirus, influenza virus,
parainfluenza, respiratory syncytial virus, coronavirus, including the causative agent of atypical
pneumonia. There are a large number of studies that have shown clinical efficiency of
umifenovir. In clinical studies of prophylactic and therapeutic efficiency of
umifenovir attended by 12400 and 1400 persons relatively. An important role in the prevention and treatment of
influenza and ARVI occupy modern nanotechnological products of natural origin such as
anaferon, aflubin, oscillococcinum having
antiviral, immunomodulatory, anti-inflammatory, disintoxicational and
antipyretic activity.